DelveInsight’s “Iron Deficiency Anemia Market Insights, Epidemiology, and Market Forecast-2034” report offers an in-depth understanding of the Iron Deficiency Anemia, historical and forecasted epidemiology as well as the Iron Deficiency Anemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
Discover Key Insights into the Iron deficiency Anemia Market with DelveInsight’s In-Depth Report @ Iron deficiency Anemia Market Size
Key Takeaways from the Iron deficiency Anemia Market Report
- In December 2024:- Dr. P. Noordzij- Postoperative anemia is common in cardiac surgery with cardiopulmonary bypass. Iron deficiency delays the recovery from postoperative anemia and may negatively affect the postoperative trajectory of cardiac surgery patients. The objective of the study is to determine the effect of treatment of postoperative iron deficiency anemia with intravenous iron on disability 90 days after surgery. This will be evaluated in a randomized placebo-controlled double blind two-center trial in which 310 elective cardiac surgery patients will be included.
- In December 2024:- RDC Clinical Pty Ltd- This is a double blind, randomised, placebo-controlled trial to evaluate orally-dosed IHAT (iron hydroxide adipate tartrate) at 2 different doses compared to placebo for increasing serum ferritin levels in iron-deficient but otherwise healthy premenopausal women over 12 weeks.
- In the United States, the total prevalent cases were around 9,510,600 cases in 2023.
- Among EU4 and the UK, UK accounted for the highest diagnosed prevalent cases of Iron deficiency Anemia, whereas France accounts for the least number of diagnosed cases.
- DelveInsight’s consultant estimates that out of the diagnosed prevalent cases of Iron deficiency Anemia patient pool, two-thirds cases are mild.
- It has been observed that Iron deficiency Anemia was more prevalent in female than male in 2023, accounting for ~65% of the cases.
- In the United States, IDA and chronic kidney disease accounted for the highest in Iron deficiency Anemia cases by pathology in 2023 (~30%).
- The leading Iron Deficiency Anemia Companies such as MegaPro Biomedical, Nemysis, Pharmacosmos A/S, Keryx Biopharmaceuticals, Pharmacosmos A/S, Tigermed Consulting Co., Ltd, Shield Therapeutics, Zeria Pharma, Keros Therapeutics, Inc., AMAG Pharma, JW Pharmaceutical, and others
- Promising Iron Deficiency Anemia Therapies such as MPB-1514 (IOP Injection), IDAX (IHAT-02), Ferric Derisomaltose, Low Dose IHAT, ferric citrate, iron isomaltoside 1000 (Monofer Registered ), Ferric carboxymaltose, Ferric Maltol, Z-213, KER-047, Ferumoxytol, venoferrum(iron sucrose), Z-213, and others
Stay ahead in the Iron deficiency Anemia Therapeutics Market with DelveInsight’s Strategic Report @ Iron deficiency Anemia Market Outlook
Iron Deficiency Anemia Epidemiology Segmentation in the 7MM
- Total Prevalence of Iron Deficiency Anemia
- Prevalent Cases of Iron Deficiency Anemia by severity
- Gender-specific Prevalence of Iron Deficiency Anemia
- Diagnosed Cases of Episodic and Chronic Iron Deficiency Anemia
Download the report to understand which factors are driving Iron deficiency Anemia epidemiology trends @ Iron deficiency Anemia Prevalence
Iron deficiency Anemia Marketed Drugs
- MONOFER (Iron Isomaltoside 1000/ Monoferric/ ferricderisomaltose/ NS-32): Pharmacosmos Therapeutics
Monoferric (ferric derisomaltose) is an intravenous iron replacement product, developed by Pharmacosmos Therapeutics. It is a complex of iron (III) hydroxide and derisomaltose, an iron carbohydrate oligosaccharide that releases iron. Iron binds to transferrin for transport to erythroid precursor cells to be incorporated into hemoglobin. The drug was approved in 30 countries outside of the US in 2009, later on in 2020 the US FDA granted approval to the drug for the treatment of the drug. In March 2022, this drug was approved in Japan under the name MONOVER.
- FERACCRU/ACCRUFeR (Ferric Maltol/ ST10): Shield Therapeutics
FERACCRU/ACCRUFeR is a novel oral product that addresses the needs of patients who cannot tolerate existing oral iron products and offers a clear alternative to IV iron therapy. In the European market the drug is marketed by the name of FERACCRU. In July 2019, the company announced that the US FDA approved ACCRUFeR for the treatment of iron deficiency in adults. In February 2016, the company announced that the EU granted Centralized Marketing Authorization the drug for the treatment of IDA in adult patients with inflammatory bowel disease (IBD). However, in March 2018, the company announced that the European Commission has adopted the decision to extend the approved indication for FERACCRU to include treatment of all adults with iron deficiency (ID) with or without anemia.
Emerging Iron deficiency Anemia Drugs
- MPB-1514 (IOP Injection): MegaPro Biomedical
MPB-1514 (IOP Injection), developed by MegaPro Biomedical, is the non- sugar iron injection being developed for the treatment of IDA. It is highly secure as coated with PEG with good macrophage phagocytic results, high doses can be injected, which can effectively increase the number of red blood cells without frequent injections, providing greater convenience and compliance with doctor’s order for patients. The Phase I clinical trial has been completed. The Phase II clinical trial has been completed the recruitment of the patients in the United States in third quarter of 2020.
- IDAX (IHAT-02): Nemysis
IHAT-02/ IDAX, is novel oral iron formulation, the first natural ferritin mimic, where a tartrate salt is used to “dope” the ferrihydrite nanocore of ferritin, in an adipate buffer. IHAT (Iron Hydroxide Adipate Tartrate) is well absorbed and preserves the gut microbiome. Absorption studies and early nutritional trials in human have shown that IHAT is absorbed efficiently and corrects markers of iron deficiency, without the burden of gastrointestinal side effects. The product is able to closely mimic normal iron absorption in the gut. Currently the drug is being evaluated in a Phase II clinical trial for the treatment of Iron deficiency/ Anemia. The company was the first to file a nano iron [IHAT nano-ferric (III)] for approval by the European Food Safety Authority.
Iron deficiency Anemia Therapies and Companies
- MPB-1514 (IOP Injection): MegaPro Biomedical
- IDAX (IHAT-02): Nemysis
- Ferric Derisomaltose: Pharmacosmos A/S
- Ferric citrate: Keryx Biopharmaceuticals
- Iron isomaltoside 1000 (Monofer Registered): Pharmacosmos A/S
- Ferric carboxymaltose: Tigermed Consulting Co., Ltd
- Ferric Maltol: Shield Therapeutics
- Z-213: Zeria Pharma
- KER-047: Keros Therapeutics, Inc.
- Ferumoxytol: AMAG Pharma
- venoferrum(iron sucrose): JW Pharmaceutical
- Z-213: Zeria Pharma
Get In-Depth Knowledge on Iron deficiency Anemia Market Trends and Forecasts with DelveInsight @ Iron deficiency Anemia Treatment Market
Iron deficiency Anemia Market Outlook
To effectively treat IDA, it is essential to diagnose and eliminate the cause of iron deficiency while simultaneously maintaining dietary management and iron supplementation. The first line of treatment in patients without contraindications is oral supplementation. Currently, IDA treatment mainly involves oral iron therapy, which includes iron supplements, over-the-counter (OTC) drugs, approved therapies, Parenteral Iron Therapy (intravenous (IV) therapies), blood transfusions, surgery, and other available treatment options. If the patient has chronic kidney disease (CKD) and IDA, the doctor may recommend erythropoiesis-stimulating agents (ESA).
Scope of the Iron deficiency Anemia Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Iron deficiency Anemia Companies- MegaPro Biomedical, Nemysis, Pharmacosmos A/S, Keryx Biopharmaceuticals, Pharmacosmos A/S, Tigermed Consulting Co., Ltd, Shield Therapeutics, Zeria Pharma, Keros Therapeutics, Inc., AMAG Pharma, JW Pharmaceutical, and others
- Iron Deficiency Anemia Therapies- MPB-1514 (IOP Injection), IDAX (IHAT-02), Ferric Derisomaltose, Low Dose IHAT, ferric citrate, iron isomaltoside 1000 (Monofer Registered ), Ferric carboxymaltose, Ferric Maltol, Z-213, KER-047, Ferumoxytol, venoferrum(iron sucrose), Z-213, and others
- Iron deficiency Anemia Therapeutic Assessment: Iron deficiency Anemia Current marketed and Iron deficiency Anemia Emerging Therapies
- Iron deficiency Anemia Market Dynamics: Iron deficiency Anemia Market drivers and Iron deficiency Anemia Market Barriers
Unlock Strategic Insights with DelveInsight’s Comprehensive Iron deficiency Anemia Market Report @ Iron deficiency Anemia Market Drivers and Barriers
Table of Content
1 Key Insights
2 Report Introduction
3 Executive Summary
4 Key Events
5 Epidemiology and Market Forecast Methodology
6 Iron deficiency Anemia Market Overview at a Glance
7 Disease Background and Overview: Iron deficiency Anemia
8 Treatment and Management
9 Epidemiology and Patient Population
10 Patient Journey
11 Marketed Therapies
12 Emerging Therapies
13 Iron deficiency Anemia: 7 Major Market Analysis
14 Unmet needs
15 SWOT Analysis
16 KOL Views
17 Market Access and Reimbursement
18 Appendix
19 DelveInsight Capabilities
20 Disclaimer
21 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage